- Home
- SPFI vs GHRS Comparison
SPFI vs GHRS Comparison
Compare SPFI & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | GHRS |
|---|---|---|
| Founded | 1941 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 794.2M | 947.2M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPFI | GHRS |
|---|---|---|
| Price | $42.62 | $26.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $46.00 | $41.38 |
| AVG Volume (30 Days) | 161.4K | ★ 249.6K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 17.81 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.65 | N/A |
| Revenue Next Year | $9.40 | N/A |
| P/E Ratio | $51.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.34 | $11.32 |
| 52 Week High | $45.09 | $28.96 |
Technical Indicators
Market Signals| Indicator | SPFI | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 64.81 |
| Support Level | $38.32 | $12.88 |
| Resistance Level | $44.29 | N/A |
| Average True Range (ATR) | 1.15 | 1.69 |
| MACD | 0.18 | 0.47 |
| Stochastic Oscillator | 62.75 | 78.81 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.